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BRAF-V600E.3 Recent studies indicate 
CNS involvement as a predictor of 
highest mortality among ECD patients.4
First described in 1969, RDD is charac-
terized by accumulation of histiocytes 
exhibiting emperipolesis in lymph nodes, 
in the head and neck or in extranodal 
sites. Extranodal sites include the CNS, 
skin, soft tissue and gastrointestinal tract. 
The clinical presentation is typically 
painless cervical lymphadenopathy with 
leukocytosis and a fever.5 The etiology 
of RDD is unknown.6 RDD with CNS 
involvement is rare and approximately 
210 cases have been reported. CNS 
involvement typically lacks extracra-
nial lymphadenopathy and resembles 
meningioma radiologically and clini-
cally.1 Select cases have demonstrated 
a combined presentation of ECD and 
RDD.2 
In this report we describe a rare case 
presenting with headache and with 
clinically and pathologically overlapping 
features of RDD and ECD. We describe 
treatment and complications and review 
the existing literature regarding diagnosis 
and treatment for these rare conditions.
CASE REpORT
The patient is a 46-year-old gentleman 
from Mexico who was initially admitted 
to the Neurology service at Jefferson 
Hospital for Neuroscience in November 
2005 with headache, vertigo, nausea and 
vomiting and was found to have bilateral 
vertebral artery dissection with proximal 
basilar artery thrombosis (MRI Picture, 
Figure 1). He was started on anticoagula-
tion and discharged home. In June 2010 
he presented to the neurosurgery office 
with worsening headaches and a MRI 
of the brain showed bilateral tentorial 
and posterior falcine mass suggestive 
of meningioma (MRI Picture, Figure 2). 
The mass was surrounding the incisura. 
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INTRODUCTION
The histiocytoses are a group of clinically diverse diseases distinguished from one 
another based on the specific immunophenotype of the lesional cells, implying deri-
vation from the same precursor cell. Langerhans cell histiocytoses (LCH) diseases 
stem from abnormal dendritic cell lineages, while the non-Langerhans cell histiocy-
toses (non-LCH) are usually derived from an abnormal monocyte/macrophage cell 
line.1 Non-LCH with central nervous system (CNS) involvement is predictive of poor 
outcome. Histopathology is used to make a diagnosis of non-LCH. Immunohistochem-
istry and the clinical setting are used to differentiate between the various subtypes of 
non-LCH.1 The non-LCH can be divided into cutaneous non-LCH, cutaneous with a 
major systemic component, and systemic non-LCH.1 Erdheim-Chester disease (ECD) 
and Rosai-Dorfman disease (RDD) are systemic non-LCH diseases.
First described in 1930, ECD is characterized by xanthogranulomatous accumulations. 
The extent of infiltration is heterogeneous and can include skin, bones, lungs, kidneys, 
and the CNS. Approximately 500 cases have been reported so far.2 The majority of 
ECD patients harbor an activating mutation of the proto-oncogene BRAF, namely 
Figure 1
MRI Brain 11/25/2005 – No tentorial 
mass lesion
Figure 2
MRI Brain Axial Image with Gadolinium 
on 6/1/2010 – showing bilateral tento-
rial and posterior falx mass lesion
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characteristic of Rosai-Dorfman Disease. 
These histiocytes were immunohis-
tochemically positive for macrophage 
markers CD68 and CD163 (path slide 1C) 
as well as S-100 (path slide 1D, E), but 
were negative for CD1a. This immuno-
phenotype is typical of Rosai-Dorfman 
histiocytes. In contrast, macrophages 
and Erdheim-Chester histiocytes are 
immunoreactive for CD68 and CD163 
procedure for tissue diagnosis but he 
failed to do so and was lost to follow up.
The lesion consisted of an inflammatory 
infiltrate composed of lymphocytes, 
plasma cells and histiocytes (path slide 
1A). High magnification images demon-
strated intact inflammatory cells within 
the cytoplasm of many of the large 
histiocytes (path slide 1B). This phenom-
enon, known as emperipolesis, is 
General Neurosurgery
He also had an enhancing lesion in the 
ethmoid sinus. He was recommended to 
have a procedure for tissue diagnosis but 
he failed to do so and was lost to follow up.
In July 2011 he represented to the 
Jefferson Hospital ER with worsening 
symptoms and new onset diabetes insip-
idus. MRI brain, MR angiogram and CT 
sinus showed progression of the tentorial 
mass and a new sellar mass in the region 
of the pituitary gland and extensive sino-
nasal soft tissue mass extending into the 
right orbit (MRI Picture, Figure 3). On 
7/28/2011 he underwent endoscopic 
transnasal transsphenoidal resection of 
the sinonasal and sellar mass. He also 
had an enhancing lesion in the ethmoid 
sinus. He was recommended to have a 
Figure 3
MRI Brain Axial Image with Gadolinium 
7/25/2011- showing progression of b/l 
tentorial and posterior falx mass lesion
MRI Brain Sagittal Image with Gado-
linium 7/25/2011 – showing sinonasal 
and sellar mass lesions Path Slide 1 
First operation A-E.  A. Inflammatory infiltrate composed of lymphocytes, plasma cells, 
and histiocytes (Hematoxylin and Eosin, 200X).  B. High magnification (Hematoxylin 
and Eosin, 1000X) demonstrates a typical Rosai-Dorfman histiocyte with neutrophils 
and plasma cells undergoing emperipolesis (arrowed).  C,D. The histiocytes are strongly 
immunoreactive for CD163 (200X) and S-100 (200X) respectively. E.  High magnfication 
(1000X) confirms the presence of emperipolesis (arrowed) within S-100 immunoreactive 
histiocytes.  F.  Second operation, sheets of foamy macrophages without emperipolesis 
(H&E, 400X). mass lesions
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During the same hospitalization he 
developed left ureteroplevic junc-
tion obstruction and hydronephrosis 
requiring stent placement.
He was discharged to rehab with 
outpatient follow up. From 8/29/2011 
to 9/14/2011 he completed radiation 
therapy of 24 Gy in 12 fractions to the 
paranasal sinuses and whole brain. In 
December 2011 he was started on inter-
feron alpha and had vast improvement of 
his symptoms.
In May 2012 he was readmitted with 
worsening headache and vision, on exam 
he had left homonymous hemianopia. 
MRI of the brain showed progression 
of the tentorial mass, compressing the 
occipital lobes bilaterally (MRI Picture, 
Figure 4). He was taken to the operating 
room and underwent an occipital/suboc-
cipital craniotomy. A near total resection 
of a solid avascular mass arising from 
the tentorium was performed using a 
combined supratentorial and infratento-
rial approach. Post-operative MRI of the 
brain confirmed minimal residual on the 
right aspect of the tentorium and poste-
rior falx (MRI Picture Figure 5). 
Pathology from this resection was char-
acteristic of ECD, revealing large numbers 
of foamy macrophages (path slide 1F) with 
foci of necrosis and cholesterol clefts. 
There was no evidence of emperipolesis 
and these macrophages/histiocytes were 
immunoreactive for CD68 and CD163, 
but negative for S-100 and CD1a. This 
immunophenotype is distinctly different 
from the original resection, and with the 
patient’s clinical picture and multisystem 
involvement, points towards ECD. His 
headaches improved, and he was subse-
quently discharged home.
On June 12, 2012 he was admitted with 
an episode of unresponsiveness and 
was found to have a MRSA pneumonia 
with presumed sepsis. In the course of 
this hospitalization he was found unre-
sponsive and in ventricular fibrillation. 
A cardiac catheterization revealed non-
occlusive coronary artery disease and 
he underwent implantable cardioverter-
defibrillator placement on 6/27/12.
By June 2013 his diabetes insipidus had 
resolved and overall he was feeling much 
better. He was lost to follow up since he 
returned to Mexico, however he presented 
in September 2014 with headache, gait 
done to rule out systemic disease 
showed pulmonary interstitial thick-
ening with fibrotic changes and the 
perinephric fat stranding consistent 
with ECD. 
but negative for S-100 and CD1a. Langer-
han’s cell histiocytes are immunoreactive 
for CD68, CD163, S-100, and CD1a. While 
the resection’s pathology was consistent 
with RDD, the chest, abdomen and pelvis 
Figure 5 
Post Op MRI Brian Axial Image with 
Gadolinium 5/26/2012 – showing gross 
total resection
Figure 4 
Pre Op MRI Brain Axial Image with Gado-
linium 5/19/2012 – showing infratentorial 
and supratentorial mass
Figure  6
CT head without contrast 9/26/2014- showing hydrocephalus
CT head without contrast 10/04/2014 – post op after VP shunt showing resolution of 
hydrocephalus
3
Barros, MS et al.: A Rare Case of a Systemic Non-Langerhans Histiocytosis Presenting with Diabetes Insipidus and a Tentorial Mass
Published by Jefferson Digital Commons, 2015
9JHN JOURNAL 
General Neurosurgery 
are rare. Headaches and seizures are 
common as well as other neurological 
symptoms depending on the location of 
the lesion; constitutional symptoms are 
usually absent.5
To make a diagnosis of RDD, an excisional 
biopsy should be performed for immu-
nohistochemical and morphological 
analyses.5 The hallmark of RDD cells is 
emperipolesis or the nondestructive 
phagocytosis of lymphocytes or eryth-
rocytes.5 Cells will be positive for CD68 
(KP-1), CD163, and S100 and are negative 
for CD1a.5
It is not uncommon for patients to present 
with both ECD and another form of LCH 
or non-LCH, as evidenced in 15% of 101 
patients by Haroche et al.2 Our patient 
presented in this case report falls into 
this category, concurrently expressing 
two systemic forms, ECD and RDD.
Treatment, both surgical and non-
surgical, is similar for these two non-LCH 
diseases. For asymptomatic patients, it is 
recommended to observe, with close 
following of the disease for progression. 
However, for symptomatic patients with 
localized lesions, particularly in the CNS, 
surgical resection and/or radiotherapy 
is the treatment of choice. In a study 
involving 10 RDD patients with CNS 
involvement, 7 of them achieved remis-
sion at follow-up after surgical resection 
of the lesions.17 
Interferon alpha (IFNα) therapy is the most 
studied,7 and Haroche et al. recommends 
IFNα therapy as the initial treatment for 
patients with symptomatic ECD. In their 
survival analysis of 53 patients, treatment 
with IFNα was an independent predictor 
of survival.2 High dose IFNα is most effec-
tive for CNS and cardiac involvement as 
Haroche et al. reported symptoms did not 
resolve in response to low dose IFNα. Side 
effects of IFNα can be intolerable and 
include fatigue and depression.2 Other 
non-surgical treatments currently being 
investigated for ECD patients with a more 
disseminated disease including: metho-
trexate18, canakinumab19, vemurafenib 
(20), and interleukin-1 targeting drugs/
glucocorticoids.21 Vemurafenib, a BRAF 
inhibitor, has recently been utilized as 
an effective treatment for ECD patients 
harboring the BRAFV600E mutation with 
severe and refractory ECD, resulting in 
significant clinical improvement.2,7
of infiltrating foamy, lipid-laden histio-
cytes, characteristic multinucleated 
Touton-type giant cells, and fibrosis.2,10 
Cells are positive for CD68 and negative 
for CD1a.12 
RDD is a nonmalignant non-LCH histio-
cytosis in which histiocytes infiltrate 
lymph nodes or extranodal tissues. RDD is 
typically diagnosed in the second or third 
decade of life and is more prevalent in 
African American individuals and in males 
compared to females.5,13 Patients with 
RDD classically present with symptoms 
of fever and massive, nonpainful cervical 
lymphadenopathy. Some patients experi-
ence night sweats and weight loss as well 
as painless maculopapular eruptions.5,14 
Osteolytic bone lesions are rare in RDD, 
unlike in patients with Langerhans cell 
histiocytosis.15 20% of patients with RDD 
have spontaneous regression without 
treatment.16 In patients without treat-
ment, 70% will experience a relapsing and 
remitting course.16 
Common sites for extranodal infiltration 
include the CNS, skin, orbit and eyelid, 
upper respiratory tract, and the gastro-
intestinal tract; some reports suggest 
extranodal involvement may occur in 
up to 40% of cases.5 CNS involvement 
of RDD is commonly with dura-based, 
extra-axial involvement of the cranium; 
spinal cord and intracerebral disease 
ataxia (right greater than left cerebellar 
dysmetria), left homonymous hemianopsia 
and on non-contrast head CT was found 
to have progressive communicating hydro-
cephalus. On 9/29/2014 he underwent a 
right ventriculoperitoneal shunt placement 
for relief (CT head pre and post VP shunt, 
Figure 6). CT head with contrast showed 
some recurrence of the tentorial mass (CT 
head with contrast, Figure 7) He recovered 
well enough and was discharged to reha-
bilitation unit.
DISCUSSION
ECD is a rare systemic non-LCH involving 
xanthogranulomatous infiltration of 
tissues by foamy histiocytes (lipid-laded 
macrophages) surrounded by fibrosis.2 It 
is typically diagnosed in the fifth decade 
of life, with a mean age of 55, and is more 
prevalent in males than females. ECD is 
considered to be both a neoplastic and 
inflammatory disorder, as the disease asso-
ciates with a specific oncogenic alteration 
in the form of the BRAFV600E mutation, 
as well as a characteristic inflammatory 
pattern of cytokines and chemokines.7 
Although it is a clinically heterogeneous 
disease involving several organ systems, 
ECD patients most commonly present 
with bilateral osteosclerosis of long bones 
of the upper and lower extremities on CT 
scans.8 Other associated systemic mani-
festations include pseudotumor of the right 
heart, pericardial fibrosis, “hairy kidney” 
due to infiltration into perinephric soft 
tissue, exophthalmos, pulmonary fibrosis, 
and CNS involvement.2,9 Less than 50% of 
patients with proven ECD have neurologic 
involvement.8 The most common neuro-
logical symptoms are diabetes insipidus 
and cerebellar issues, both of which are 
part of our patient’s history.10 Lesions in 
the CNS have been specifically identified in 
the hypothalamic-pituitary axis, cavernous 
sinus, orbits, paranasal sinuses, brainstem, 
and vertebral column.8 The prognosis for 
patients with ECD is variable and depends 
on the extent of disease.2,8 Renal failure, 
cardiomyopathy, and respiratory failure 
are the most common causes of death 
in patients with ECD.8 59% of patients 
succumb to ECD after a mean follow-up 
of 32 months.1 1 
The definitive diagnosis for ECD can only 
be made via histopathology analysis and 
immunohistochemistry, with the presence 
Figure  7 
CT head with contrast 10/09/2014 – 
showing recurrence of infratentorial 
and supratentorial mass lesions
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Patients with RDD experiencing symp-
toms have nonsurgical treatment options 
such as radiotherapy, steroids or chemo-
therapy agents including vinca alkaloids 
and anthracyclines.5 ECD and RDD are 
rare diseases and treatment options 
need to be studied further in randomized 
controlled trials in order to determine the 
best treatment for these patients.
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